PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).

Vulvar Paget's disease is a rare skin tumour which affect Caucasian post-menopausal women. The disease is revealed by erythematous, eczematous, pruritus and vulvar burns. The diagnosis is often late (from a few months to several years) because the symptoms are neglected by patients or misinterpreted by doctors. The reference treatment is based on surgical excision but unfortunately local recurrences are very frequent (17 to 38% of cases). Photodynamic therapy (PDT) is already used in some dermatological pathologies and could therefore be an alternative treatment. The objective of this study

Trial Details

NCT ID

NCT03713203

Phase

NA

Sponsor

University Hospital, Lille

Status

RECRUITING

Cancer Type

Lobular Carcinoma Breast Cancer

Interventions

• pagetex PDT

Locations (sample)

• Lille, France|50.63391,3.05512

Key Eligibility Criteria

• Non-invasive, primary or recurrent vulvar Paget's disease after surgical resection
• Ability to give informed consent.
• Ability to adhere to the study protocol
• Patients must have biopsy (\< 1year) proven recurrent extra mammary Paget's disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lobular Carcinoma Breast Cancer Trials on Trialify →